Neuroblastoma kills more children under one year of age than any other extracranial solid tumor, and high-risk cases have resisted meaningful improvement in survival for decades. A team at the Hebrew University of Jerusalem has now identified a molecular accomplice: neuronal nitric oxide synthase, or nNOS, which feeds the mTOR growth-signaling pathway through nitrosative stress. Blocking nNOS, either pharmacologically with the compound BA-101 or genetically with siRNA, silenced mTOR signaling and crippled malignant behavior in human neuroblastoma cells. In a xenograft mouse model, BA-101 shrank tumors dramatically (p < 0.001). The nNOS–mTOR axis emerges as a new and targetable vulnerability. NeuroNOS Ltd., which partly funded this work, has obtained a license for the patent applications of the BA-101 molecule filed by Yissum (The Hebrew University Technology Transfer Company). The authors, in collaboration with NeuroNOS, have also demonstrated the therapeutic efficacy of BA-101 in glioblastoma.

Key takeaways:

- New survey results from The Ohio State University Wexner Medical Center find public openness to AI in health care has decreased, with only 42% of adults supportive in 2026 compared to 52% in 2024.

- Despite concerns about AI's accuracy and understanding of individual health history, 51% of adults surveyed relied on AI for important health decisions without consulting a medical professional.

- Survey participants commonly use AI to understand symptoms (62%), explain test results (44%), compare treatment options (25%), and prepare for medical appointments (20%).

Artificial intelligence is playing an ever larger role in the delivery of psychotherapy. An interdisciplinary team of University of Utah researchers has built a framework for assessing varying levels of automation in a mental health field reliant on human interaction.